Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Cash from Operating Activities
Gensight Biologics SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Cash from Operating Activities
-€15.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Operating Activities
-€142.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Cash from Operating Activities
-€18.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Operating Activities
-€41.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-12%
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Operating Activities
-€84.7m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Cash from Operating Activities
€23.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Cash from Operating Activities?
Cash from Operating Activities
-15.8m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Cash from Operating Activities amounts to -15.8m EUR.
What is Gensight Biologics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
15%
Over the last year, the Cash from Operating Activities growth was 53%. The average annual Cash from Operating Activities growth rates for Gensight Biologics SA have been 5% over the past three years , 15% over the past five years .
You don't have any saved screeners yet